Pasithea Therapeutics Corp. (KTTA) vs Lipocine Inc. (LPCN)
A side-by-side comparison of Pasithea Therapeutics Corp. and Lipocine Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
KTTA
Pasithea Therapeutics Corp.
$0.45HealthcareDelayed quote: Oct 6, 2026, 2:58 PM EDT
LPCN
Lipocine Inc.
$2.08HealthcareDelayed quote: Oct 6, 2026, 3:00 PM EDT
Total return — KTTA vs LPCN
growth of $100 · dividends reinvested · last 5yKTTA -99.4% (-63.6%/yr)LPCN -89.4% (-36.2%/yr)LPCN compounded faster over this window
Log scale — wide-divergence pair
KTTA LPCN
KTTA vs LPCN: by the numbers
- •LPCN is the larger company ($17M vs $15M market cap).
- •Both run net losses; KTTA's is the smaller (0.00% vs -755.13% net margin).
Metrics side by side
Valuation
| Metric | KTTA | LPCN |
|---|---|---|
| P/S ratio | N/A | 10.90 |
| P/B ratio | 0.30 | 0.79 |
Profitability
| Metric | KTTA | LPCN |
|---|---|---|
| Gross margin | 0.00% | -334.26% |
| Operating margin | 0.00% | -524.69% |
| Net margin | 0.00% | -755.13% |
| ROE | -42.72% | -54.45% |
| ROIC | -48.04% | -57.74% |
Growth (annualized)
| Metric | KTTA | LPCN |
|---|---|---|
| Total return CAGR (5Y) | -61.48% | -34.76% |
Frequently asked
- How have KTTA and LPCN total returns compared?
- Over the past 5 years, KTTA delivered -61.48% and LPCN delivered -34.76% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.